Urothelial Carcinoma Bladder clinical trials

Explore recruiting urothelial carcinoma bladder clinical trials.

Recruiting urothelial carcinoma bladder studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Urothelial Carcinoma Bladder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette- Guérin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

Germany, France, Netherlands, Portugal, Spain, Belgium +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Germany, Netherlands, Spain, Belgium, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

Spain, Germany, Denmark, Poland, France, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Urothelial Carcinoma Bladder trials by city

Urothelial Carcinoma Bladder clinical trials

Recruiting urothelial carcinoma bladder studies right now

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Chemoablation for Low-Grade Bladder Cancer

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)

Intervention of Bladder Cancer by CAR-T

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Also recruiting in Europe

SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Urothelial Carcinoma Bladder trials by city

Other conditions